X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs DISHMAN PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES DISHMAN PHARMA DIVIS LABORATORIES/
DISHMAN PHARMA
 
P/E (TTM) x 33.3 25.1 132.9% View Chart
P/BV x 5.4 3.3 161.7% View Chart
Dividend Yield % 0.9 0.7 137.8%  

Financials

 DIVIS LABORATORIES   DISHMAN PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
DISHMAN PHARMA
Mar-16
DIVIS LABORATORIES/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,222374 326.4%   
Low Rs784129 608.2%   
Sales per share (Unadj.) Rs153.1197.8 77.4%  
Earnings per share (Unadj.) Rs39.921.2 188.4%  
Cash flow per share (Unadj.) Rs44.634.7 128.4%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.00.8 125.4%  
Book value per share (Unadj.) Rs201.8179.9 112.2%  
Shares outstanding (eoy) m265.4780.69 329.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.61.3 514.9%   
Avg P/E ratio x25.111.9 211.6%  
P/CF ratio (eoy) x22.57.2 310.4%  
Price / Book Value ratio x5.01.4 355.3%  
Dividend payout %25.09.4 265.4%   
Avg Mkt Cap Rs m266,26620,306 1,311.3%   
No. of employees `0009.70.8 1,174.3%   
Total wages/salary Rs m4,6875,355 87.5%   
Avg. sales/employee Rs Th4,175.019,252.7 21.7%   
Avg. wages/employee Rs Th481.56,459.5 7.5%   
Avg. net profit/employee Rs Th1,089.32,064.1 52.8%   
INCOME DATA
Net Sales Rs m40,64315,961 254.6%  
Other income Rs m749265 282.2%   
Total revenues Rs m41,39216,226 255.1%   
Gross profit Rs m14,4604,103 352.4%  
Depreciation Rs m1,2331,091 113.1%   
Interest Rs m23944 2.4%   
Profit before tax Rs m13,9532,334 597.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,349624 537.1%   
Profit after tax Rs m10,6041,711 619.7%  
Gross profit margin %35.625.7 138.4%  
Effective tax rate %24.026.7 89.8%   
Net profit margin %26.110.7 243.4%  
BALANCE SHEET DATA
Current assets Rs m40,10511,018 364.0%   
Current liabilities Rs m6,5959,517 69.3%   
Net working cap to sales %82.59.4 876.8%  
Current ratio x6.11.2 525.3%  
Inventory Days Days119110 107.3%  
Debtors Days Days8135 231.6%  
Net fixed assets Rs m19,99516,304 122.6%   
Share capital Rs m531161 328.9%   
"Free" reserves Rs m53,04312,907 411.0%   
Net worth Rs m53,57414,516 369.1%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m61,58529,805 206.6%  
Interest coverage x618.43.5 17,816.5%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.70.5 123.2%   
Return on assets %17.38.9 193.7%  
Return on equity %19.811.8 167.9%  
Return on capital %26.117.5 148.8%  
Exports to sales %024.8 0.0%   
Imports to sales %25.23.7 675.6%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs m10,259596 1,720.5%   
Fx inflow Rs m35,3844,952 714.6%   
Fx outflow Rs m10,399697 1,492.3%   
Net fx Rs m24,9854,255 587.2%   
CASH FLOW
From Operations Rs m11,4932,786 412.5%  
From Investments Rs m-11,372-1,529 743.8%  
From Financial Activity Rs m-93-941 9.9%  
Net Cashflow Rs m28316 9.0%  

Share Holding

Indian Promoters % 52.0 61.4 84.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 3.7 318.9%  
FIIs % 19.0 12.7 149.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 22.1 77.8%  
Shareholders   31,796 46,261 68.7%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   AUROBINDO PHARMA  MERCK LTD  NOVARTIS  FULFORD INDIA  ORCHID PHARMA LTD  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jun 19, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS